Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models

Mol Med Rep. 2022 Mar;25(3):91. doi: 10.3892/mmr.2022.12607. Epub 2022 Jan 18.

Abstract

Animal models for Parkinson's disease (PD) are very useful in understanding the pathogenesis of PD and screening for new therapeutic approaches. The present study compared two commonly used neurotoxin‑induced mouse models of chronic PD to guide model selection, explore the pathogenesis and mechanisms underlying PD and develop effective treatments. The chronic PD mouse models were established via treatment with rotenone or 1‑methyl‑4‑phenyl‑1,2,3,6-tetrahydropyridine (MPTP) for 6 weeks. The effects of rotenone and MPTP in the mice were compared by assessing neurobehavior, neuropathology and mitochondrial function through the use of the pole, rotarod and open field tests, immunohistochemistry for tyrosine hydroxylase (TH), glial fibrillary acidic protein (GFAP), ionized calcium‑binding adapter molecule 1 (Iba‑1), neuronal nuclear antigen (NeuN) and (p)S129 α‑synuclein, immunofluorescence for GFAP, Iba‑1 and NeuN, western blotting for TH, oxygen consumption, complex I enzyme activity. The locomotor activity, motor coordination and exploratory behavior in both rotenone and MPTP groups were significantly lower compared with the control group. However, behavioral tests were no significant differences between the two groups. In the MPTP group, the loss of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta, the reduction of the tyrosine hydroxylase content in the SN and striatum and the astrocyte proliferation and microglial activation in the SN were more significant compared with the rotenone group. Notably, mitochondrial‑dependent oxygen consumption and complex I enzyme activity in the SN were significantly reduced in the rotenone group compared with the MPTP group. In addition, Lewy bodies were present only in SN neurons in the rotenone group. Although no significant differences in neurobehavior were observed between the two mouse models, the MPTP model reproduced the pathological features of PD more precisely in terms of the loss of DA neurons, decreased dopamine levels and neuroinflammation in the SN. On the other hand, the rotenone model was more suitable for studying the role of mitochondrial dysfunction (deficient complex I activity) and Lewy body formation in the SN, which is a characteristic pathological feature of PD. The results indicated that MPTP and rotenone PD models have advantages and disadvantages, therefore one or both should be selected based on the purpose of the study.

Keywords: 1‑methyl‑4‑phenyl‑1; 2; 3; 6-tetrahydropyridine; Parkinson's disease; mouse model; neurotoxin; rotenone.

Publication types

  • Comparative Study

MeSH terms

  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Animals
  • Avoidance Learning / physiology
  • Blotting, Western
  • Chronic Disease
  • DNA-Binding Proteins / metabolism
  • Disease Models, Animal*
  • Dopaminergic Neurons / cytology
  • Glial Fibrillary Acidic Protein / metabolism
  • Humans
  • Immunohistochemistry
  • Mice
  • Mice, Inbred C57BL
  • Motor Activity / physiology
  • Nerve Tissue Proteins / metabolism
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / metabolism*
  • Parkinson Disease, Secondary / physiopathology*
  • Rotenone
  • Substantia Nigra / cytology
  • Tyrosine 3-Monooxygenase / metabolism

Substances

  • DNA-Binding Proteins
  • Glial Fibrillary Acidic Protein
  • Nerve Tissue Proteins
  • NeuN protein, mouse
  • glial fibrillary astrocytic protein, mouse
  • Rotenone
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
  • Tyrosine 3-Monooxygenase

Grants and funding

The present study was supported by grants from the National Natural Science Foundation of China (grant no. 81971291), the Natural Science Foundation of Zhejiang Province (grant no. LY19C070001), the School of Laboratory Medicine and Life Sciences, Wenzhou Medical University (grant no. 437601607), the Beijing Friendship Hospital, Capital Medical University (grant no. YYZZ201920) and the Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A).